1-5 of 5
David Polidori
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series

Sudha S. Shankar, Adrian Vella, Ralph H. Raymond, Myrlene A. Staten, Roberto A. Calle, Richard N. Bergman, Charlie Cao, Danny Chen, Claudio Cobelli, Chiara Dalla Man, Mark Deeg, Jennifer Q. Dong, Douglas S. Lee, David Polidori, R. Paul Robertson, Hartmut Ruetten, Darko Stefanovski, Maria T. Vassileva, Gordon C. Weir, David A. Fryburg
Journal: Diabetes Care
Diabetes Care 2016;39(9):1602–1613
https://doi.org/10.2337/dc15-0931
Published: 12 July 2016
View article titled, Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series
Open the PDF for Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series in another window
Includes: Supplementary data
Journal Articles

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside

Sunder Mudaliar, David Polidori, Brian Zambrowicz, Robert R. Henry
Journal: Diabetes Care
Diabetes Care 2015;38(12):2344–2353
https://doi.org/10.2337/dc15-0642
Published: 19 November 2015
View article titled, Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: <subtitle>From Bench to Bedside</subtitle>
Open the PDF for Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: <subtitle>From Bench to Bedside</subtitle> in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

Robert R. Henry, Payal Thakkar, Cindy Tong, David Polidori, Maria Alba
Journal: Diabetes Care
Diabetes Care 2015;38(12):2258–2265
https://doi.org/10.2337/dc15-1730
Published: 20 October 2015
View article titled, Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
Open the PDF for Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes in another window
Includes: Supplementary data
Journal Articles

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study

David Polidori, PHD, Sue Sha, MD, Sunder Mudaliar, MD, Theodore P. Ciaraldi, PHD, Atalanta Ghosh, PHD, Nicole Vaccaro, BS, Kristin Farrell, BS, Paul Rothenberg, MD, Robert R. Henry, MD
Journal: Diabetes Care
Diabetes Care 2013;36(8):2154–2161
https://doi.org/10.2337/dc12-2391
Published: 11 July 2013
View article titled, Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: <subtitle>Results of a randomized, placebo-controlled study</subtitle>
Open the PDF for Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: <subtitle>Results of a randomized, placebo-controlled study</subtitle> in another window
Includes: Supplementary data
Journal Articles

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

Julio Rosenstock, MD, Naresh Aggarwal, MD, David Polidori, PHD, Yue Zhao, PHD, Deborah Arbit, MD, Keith Usiskin, MD, George Capuano, PHD, William Canovatchel, MD, for the Canagliflozin DIA 2001 Study Group
Journal: Diabetes Care
Diabetes Care 2012;35(6):1232–1238
https://doi.org/10.2337/dc11-1926
Published: 11 May 2012
View article titled, Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
Open the PDF for Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes in another window
Includes: Supplementary data